Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nuclear Medicine

Nuclear Medicine With the availability of virtually nontoxic low-radiation radiopharmaceuticals, nuclear medicine now contributes to diagnosis and treatment in every medical and surgical specialty. The unique demonstration of functional anatomy (including remarkable advances in receptor and antigen localization) by nuclear medicine techniques has been made possible by the interdisciplinary collaboration of teams that include not only the nuclear physician but also chemists, physicists, radiopharmacists, engineers, and technologists. The development of new radiolabeled tracer molecules and more sophisticated computer-interfaced imaging instruments has led to significant advances in a number of clinically important areas. Antitumor antibodies or immunoglobulin fragments (papain-cleaved Fab and the larger pepsin-cleaved F(ab')2, labeled with iodine 131, indium 111, or, more recently, technetium Tc 99m, have been successfully employed in tumor detection.1 Studies of several such systems, including anticarcinoembryonic antigen antibody and antibody directed against melanoma-associated proteins, indicate sensitivities of 80% to 90%. Some of the patients studied have http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Nuclear Medicine

Silberstein, Edward B.
JAMA , Volume 254 (16) – Oct 25, 1985
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/nuclear-medicine-PJS0n0Uxhd

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1985 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1985.03360160157046
Publisher site
See Article on Publisher Site

Abstract

With the availability of virtually nontoxic low-radiation radiopharmaceuticals, nuclear medicine now contributes to diagnosis and treatment in every medical and surgical specialty. The unique demonstration of functional anatomy (including remarkable advances in receptor and antigen localization) by nuclear medicine techniques has been made possible by the interdisciplinary collaboration of teams that include not only the nuclear physician but also chemists, physicists, radiopharmacists, engineers, and technologists. The development of new radiolabeled tracer molecules and more sophisticated computer-interfaced imaging instruments has led to significant advances in a number of clinically important areas. Antitumor antibodies or immunoglobulin fragments (papain-cleaved Fab and the larger pepsin-cleaved F(ab')2, labeled with iodine 131, indium 111, or, more recently, technetium Tc 99m, have been successfully employed in tumor detection.1 Studies of several such systems, including anticarcinoembryonic antigen antibody and antibody directed against melanoma-associated proteins, indicate sensitivities of 80% to 90%. Some of the patients studied have

Journal

JAMA – American Medical Association

Published: Oct 25, 1985

There are no references for this article.